Emotional Blunting on Antidepressants

Home > Depression > Emotional Blunting on Antidepressants

Emotional blunting was reported by 46% of 669 depressed adults taking an antidepressant in an internet survey run across several countries (Goodwin and colleagues, Journal of Affective Disorders, 2017). Rates were slightly higher in men than women (52% versus 44%) and did not differ meaningfully between drugs, although blunting appeared less frequent with bupropion. In a separate survey of 1,829 New Zealanders who had taken antidepressants, 60% endorsed "feeling emotionally numb" and 42% a reduction in positive feelings (Read and colleagues, Psychiatry Research, 2014).

The patient version of that statistic is a sentence I hear in some form most months: "I'm not sad anymore, but I'm not anything." The rating scale says the treatment worked. The person in the chair says something went missing along with the sadness, and they are often already deciding whether to stop. Both observations are usually accurate, and the clinical work is sorting out how much of the flatness belongs to the medication and how much to the depression that remains.

Nearly half of treated patients report blunting, and the figure depends on how you ask

The 46% figure comes from a validated instrument. Price, Cole and Goodwin first interviewed patients and found that most felt able to tell the emotional effects of their SSRI apart from their depression (Price and colleagues, British Journal of Psychiatry, 2009). That work produced the Oxford Questionnaire on the Emotional Side-effects of Antidepressants, which in 207 patients resolved into four dimensions: not caring, emotional detachment, reduction in positive emotions, and a general reduction in emotions (Price and colleagues, Journal of Affective Disorders, 2012).

Later surveys using a successor version of the scale, the Oxford Depression Questionnaire, point the same direction. Among 752 adults on antidepressants in Brazil, Canada, and Spain who reported blunting in the prior six weeks, 44% rated it extremely severe, 56% attributed it mainly to their depression, 45% believed their antidepressant was blunting their emotions, and 39% were considering stopping or had already stopped because of it (Christensen and colleagues, Annals of General Psychiatry, 2022).

The range in the literature is wide. A systematic review of 50 studies found reported prevalence of antidepressant-associated apathy between 5.8% and 50% overall, and between 20% and 92% in SSRI samples (Masdrakis and colleagues, Acta Neuropsychiatrica, 2023). That heterogeneity likely reflects differing definitions, instruments, and self-selected online samples, so the percentages describe patients who notice the problem rather than the population as a whole.

Blunting and residual depression overlap, and the time course helps separate them

Anhedonia, the loss of interest and pleasure, is a core symptom of depression, so a flat patient on an antidepressant may simply be an incompletely treated patient. In Goodwin's survey, blunting scores correlated with depression scores (r = 0.52). In Christensen's sample, 72% of patients in an acute episode rated their blunting extremely severe, compared with 25% of those in remission.

Yet remission did not return patients to baseline. Goodwin's patients with low residual depression scores still scored higher than recovered, formerly depressed controls (35.1 versus 25.7). In other words, part of the flatness tracks the depression and part persists after it lifts, which is broadly consistent with a medication effect layered on residual illness. Importantly, a one-time survey cannot assign cause.

In the office, I ask patients to date the flatness. Features pointing toward the medication: the numbness appeared or deepened after the drug started or the dose went up, while sleep, appetite, and sadness were improving; it covers negative and positive emotions alike (the patient who cannot cry at a funeral and also cannot get irritated at a sibling); and it moves with dose. Features pointing toward residual depression: the anhedonia predated the prescription, it travels with fatigue, poor concentration, and low drive, and it lifts as the other symptoms lift. Among 15 patients with SSRI-induced sexual dysfunction, 80% also described clinically significant blunting of several emotions, and blunting scores did not correlate with depression severity (Opbroek and colleagues, International Journal of Neuropsychopharmacology, 2002). When sexual side effects and emotional numbness arrive together on a serotonergic drug, the drug is the likelier explanation.

The likely mechanism is reduced sensitivity to reward and punishment

The strongest evidence that antidepressants themselves blunt emotion comes from people who were never depressed. In a double-blind study at the University of Copenhagen, 66 healthy volunteers received 20 mg of escitalopram (n = 32) or placebo (n = 34) for at least 21 days (Langley and colleagues, Neuropsychopharmacology, 2023). On two learning tasks, the escitalopram group showed reduced reinforcement sensitivity, meaning their choices were less shaped by the rewards and punishments they received, while memory, inhibition, and cognitive flexibility did not differ. Because the volunteers had no depression, residual illness cannot explain the result.

The finding fits what patients describe. If a serotonergic drug lowers the weight the brain gives to outcomes, both good and bad events land more softly. That dampening of reactivity to negative events is likely part of how SSRIs relieve depression and anxiety, so the therapeutic effect and the side effect may share machinery. Accordingly, the practical goal is the dose and drug at which the depression stays treated and the person still feels like themselves.

The effect appears dose-dependent and reversible

Across the 50 studies in the 2023 systematic review, antidepressant-associated apathy emerged independently of diagnosis, age, and treatment outcome, appeared dose-dependent, and was reversible, with dose reduction the most commonly used remedy (Masdrakis and colleagues, 2023). An earlier clinical review described the same profile: insidious onset, higher likelihood at higher SSRI doses, and resolution when the drug is stopped (Sansone and Sansone, Psychiatry, 2010).

Much of that evidence is case series and open-label reports, and I know of no randomized dose-ranging trial that used blunting as its primary outcome; Goodwin's survey did not analyze dose at all. The dose-response claim is clinically plausible and repeatedly observed, and it has not been tested the way an efficacy claim would be.

Some antidepressants appear to blunt less, with uneven evidence behind each

Bupropion. In the 2017 survey, blunting appeared less frequent with bupropion, though the authors noted the sample was too small to compare drugs reliably, and the 2023 review lists bupropion among treatments with some supporting data. Bupropion acts on noradrenaline and dopamine without inhibiting serotonin reuptake, so a lower rate is plausible. The evidence is observational and consistent, with no randomized head-to-head trial.

Vortioxetine. The COMPLETE study enrolled 143 adults with major depression who had a partial response and emotional blunting on an SSRI or SNRI, and switched them to vortioxetine 10 to 20 mg per day for eight weeks (Fagiolini and colleagues, Journal of Affective Disorders, 2021). Blunting scores fell by 29.8 points, 50% of patients no longer reported blunting on a standardized question, and 47% were in remission at week 8. The study was open-label with no comparison group and no observation phase before the switch, so some of the improvement likely reflects time, expectation, and the natural course of a partial response.

Agomelatine. A 24-week randomized, double-blind trial compared agomelatine (n = 164) with escitalopram (n = 160) in major depression, with similar improvement in both arms (Corruble and colleagues, International Journal of Neuropsychopharmacology, 2013). Among the 45 patients who completed the emotional side-effects questionnaire, 28% on agomelatine versus 60% on escitalopram felt their emotions lacked intensity, and 16% versus 53% felt that things they had cared about no longer seemed important. The emotional data come from a small subsample, and agomelatine is not approved in the United States, so for American patients this result mainly supports the idea that drug choice matters.

Finally, none of these comparisons is a blinded, randomized trial against an SSRI with blunting as the primary outcome. Choosing bupropion or vortioxetine for a blunted patient rests on plausible mechanism and consistent lower-grade evidence, a reasonable basis for an individual decision and a weak one for a general claim.

What I change when a patient reports blunting

Patients usually raise blunting as an aside, sometimes only after a partner has noticed. I measure it with the Oxford questionnaire alongside a depression scale at the same visit, so changes are tracked rather than remembered. The steps below are what prescribers typically do; every decision is individual and made with the prescriber, and nothing here is a schedule to follow on your own.

• Treat the depression fully first. When residual symptoms are still prominent, the blunting is more likely to be the illness, and changing drugs prematurely risks losing the ground already gained. The depression page covers how I judge whether a response is complete.
• Lower the dose when the response is secure. If mood has been stable for months and the dose sits above the lowest effective one, a careful reduction is the most evidence-supported first move, with mood tracked at each step.
• Switch. When blunting persists at the lowest effective dose, switching to bupropion or to vortioxetine is the usual next option, with the caveats above. Switching between two SSRIs rarely helps with this particular problem.
• Add bupropion to the SSRI. This combination is common in practice and off-label for blunting. The direct evidence is thin, and it is most reasonable when the SSRI is doing necessary work for anxiety or obsessive symptoms that bupropion alone would not cover.
• Add psychotherapy aimed at anhedonia. A randomized trial of 85 adults with severely low positive affect compared 15 sessions of positive affect treatment against a cognitive behavioral therapy aimed at negative affect; positive affect treatment produced larger improvements in clinical status (d = 0.64) and in reward anticipation and response (Craske and colleagues, Journal of Consulting and Clinical Psychology, 2023). The trial did not study medication-induced blunting, although its target, low positive affect, is the same complaint. See CBT in this practice and the broader question of medication, therapy, or both.

Adolescents deserve a specific note. The 2010 review observed that insight into this side effect is often low in children and adolescents, so I ask parents directly whether their teenager seems flatter or cares less than before the medication. That question is part of adolescent care here and of every medication management visit for adults.

Blunting drives people to stop, and stopping carries its own cost

In the 2022 survey, 39% of patients with blunting were considering stopping or had already stopped because of it. In a Depression and Bipolar Support Alliance survey of 896 people with unipolar or bipolar depression, emotional blunting was one of several experiences that had led more than a third of respondents to discontinue a medication (Rosenblat and colleagues, Journal of Affective Disorders, 2019).

The other side of the ledger is relapse. Across 31 randomized trials and 4,410 patients who had responded to an antidepressant, continuing the drug reduced the odds of relapse by 70%, with average relapse of 41% on placebo and 18% on continued treatment over mostly 12 months (Geddes and colleagues, Lancet, 2003). A patient who quietly stops because they feel numb accepts roughly a doubling of relapse risk to solve a problem a dose change or switch would often have addressed. When a prescriber has dismissed the complaint, a second opinion is a better next step than stopping. When blunting sits on top of a depression that has failed two or more adequate trials, the treatment-resistant depression framework applies.

Who this practice fits, and when to go elsewhere

This fits adults and adolescents whose depression has improved on an antidepressant and who feel flat, detached, or indifferent in a way that started or worsened with treatment. It also fits patients told the numbness is "just the depression" who want both possibilities assessed, and patients weighing a switch who want the evidence laid out first. Patients unsure which kind of clinician handles this: it belongs with a prescriber.

Some situations belong elsewhere first. Flatness that alternates with elevated mood, reduced need for sleep, or unusual productivity warrants evaluation for bipolar disorder before any antidepressant adjustment. New apathy with memory loss or neurological symptoms needs a medical workup. An active suicidal crisis needs an emergency department today.

Cost and booking

Initial evaluations run 60 to 90 minutes, long enough to take a full medication history, date the blunting against each dose change, and administer the rating scales repeated at follow-up. The practice is out-of-network with all insurance plans. You pay directly and receive a superbill to submit for reimbursement; many NYC plans with out-of-network benefits reimburse a meaningful share once the deductible is met. The numbers are laid out at fees and out-of-network costs, and you can check your out-of-network benefits before booking.

Bring a list of every antidepressant you have taken with doses and approximate dates, and note when the flatness began. Schedule a consultation or call (646) 893-4309.

Related

Depression · Medication management · Treatment-resistant depression · Medication vs therapy vs both · CBT · Second opinions · Adolescent psychiatry · What type of doctor treats depression · Antidepressant sexual side effects · Antidepressants and weight gain · Depression with ADHD: combining medications · Anxiety medication options · How long antidepressants take to work · Lexapro vs Zoloft · SSRIs for teens · Stopping antidepressants · Wellbutrin vs SSRIs

When Depression Becomes an Emergency

Emotional flatness can mask suicidal thinking, because a person who feels nothing may also describe caring less whether they live, and any dose reduction, switch, or discontinuation is a period to watch mood closely. Suicidal thoughts without immediate crisis still warrant same-day or next-day psychiatric evaluation.

Frequently Asked Questions

How common is emotional blunting on antidepressants?

In a 2017 survey of 669 depressed adults taking an antidepressant, 46% reported emotional blunting, with no meaningful difference between drugs and a somewhat lower rate on bupropion. A 2014 survey of 1,829 New Zealanders found 60% felt emotionally numb. Across 50 studies, rates ranged from about 6% to 50%, and higher in SSRI samples, so the figure depends on how the question is asked.

Is emotional blunting a side effect or a symptom of depression?

Usually some of each. Blunting scores correlate with residual depression severity, and patients in remission report far less of it. Yet patients with low residual symptoms still score higher than recovered controls, and healthy volunteers given escitalopram for three weeks showed reduced sensitivity to reward and punishment. Flatness that began after the drug or a dose increase, covers positive and negative emotions alike, and moves with dose points toward the medication.

Which antidepressants cause the least emotional blunting?

Bupropion appeared to blunt less in the 2017 survey, and a 2023 systematic review lists bupropion, agomelatine, and a few other agents as having some supporting data. In an open-label study, switching 143 partially responding patients to vortioxetine cut blunting scores substantially, with half no longer reporting it at eight weeks. None of this comes from a blinded randomized trial, so the evidence is suggestive rather than settled.

Does lowering the dose fix emotional blunting?

Often. Dose reduction is the most commonly used strategy in the published literature, which describes the effect as dose-dependent and reversible, although that evidence is largely case series and open-label reports. A reduction makes sense when the depression has been stable for months and the dose sits above the lowest effective one. It should be planned with the prescriber and paired with mood tracking, since the depression can return as the dose falls.

Does emotional blunting go away on its own?

When it reflects residual depression, it tends to lift as the depression continues to improve, which is one reason I treat the depression fully before changing drugs. When it reflects the medication, it usually persists at the same dose and resolves after a reduction, a switch, or discontinuation. Dating the onset against each prescription change is the most useful information to bring to that conversation.

Should I stop my antidepressant if I feel numb?

Not on your own. Across 31 randomized trials, continuing an antidepressant after response cut relapse from 41% to 18% over roughly a year. Blunting is a legitimate reason to change treatment, and 39% of patients with it are considering stopping. The better move is a dose reduction, a switch, or an added medication or therapy arranged with your prescriber. If your prescriber dismisses the complaint, seek a second opinion before discontinuing.

Sources

1. Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31–35. PMID 28628765
2. Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res. 2014;216(1):67–73. PMID 24534123
3. Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195(3):211–217. PMID 19721109
4. Price J, Cole V, Doll H, Goodwin GM. The Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQuESA): development, validity, reliability and sensitivity to change. J Affect Disord. 2012;140(1):66–74. PMID 22387055
5. Christensen MC, Ren H, Fagiolini A. Emotional blunting in patients with depression. Part I: clinical characteristics. Ann Gen Psychiatry. 2022;21(1):10. PMID 35379283
6. Masdrakis VG, Markianos M, Baldwin DS. Apathy associated with antidepressant drugs: a systematic review. Acta Neuropsychiatr. 2023;35(4):189–204. PMID 36644883
7. Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont). 2010;7(10):14–18. PMID 21103140
8. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002;5(2):147–151. PMID 12135539
9. Langley C, Armand S, Luo Q, et al. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. Neuropsychopharmacology. 2023;48(4):664–670. PMID 36683090
10. Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021;283:472–479. PMID 33516560
11. Corruble E, de Bodinat C, Belaïdi C, Goodwin GM. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16(10):2219–2234. PMID 23823799
12. Craske MG, Meuret AE, Echiverri-Cohen A, Rosenfield D, Ritz T. Positive affect treatment targets reward sensitivity: a randomized controlled trial. J Consult Clin Psychol. 2023;91(6):350–366. PMID 36892884
13. Rosenblat JD, Simon GE, Sachs GS, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2019;243:116–120. PMID 30241026
14. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661. PMID 12606176